My colleagues and I recently attended the EURORDIS Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies. We came away with an understanding that collaboration with all our stakeholders will be essential to improving access for Rare Disease patients. Not only do we need multi-stakeholder dialogues between regulatory, payers, manufacturers and patient advocates, but we need agreement on value determination and reimbursement strategies across the EU. Partnerships will be key to creating strong pathways for patients to get access to the medications they need, and we are pulling these insights through our partnership with EURORDIS into our strategy moving forward.
Clinical data management, Clinical trails, Pharmacovigilance